Home › Compare › KSPHF vs DIVO

KSPHF vs DIVO: Dividend Comparison 2026

KSPHF yields 2.99% · DIVO yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KSPHF wins by $3.00M in total portfolio value
10 years
KSPHF
KSPHF
● Live price
2.99%
Share price
$25.77
Annual div
$0.77
5Y div CAGR
70.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.03M
Annual income
$2,313,976.52
Full KSPHF calculator →
DIVO
DIVO
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full DIVO calculator →

Portfolio growth — KSPHF vs DIVO

📍 KSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKSPHFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KSPHF + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
KSPHF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KSPHF
Annual income on $10K today (after 15% tax)
$254.17/yr
After 10yr DRIP, annual income (after tax)
$1,966,880.04/yr
DIVO
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, KSPHF beats the other by $1,966,115.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KSPHF + DIVO for your $10,000?

KSPHF: 50%DIVO: 50%
100% DIVO50/50100% KSPHF
Portfolio after 10yr
$1.53M
Annual income
$1,157,437.86/yr
Blended yield
75.69%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KSPHF buys
0
DIVO buys
0
No recent congressional trades found for KSPHF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKSPHFDIVO
Forward yield2.99%4.00% ✓
Annual dividend / share$0.77$2.00 ✓
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR70.9% ✓5%
Portfolio after 10y$3.03M$28.0K ✓
Annual income after 10y$2,313,976.52 ✓$899.19
Total dividends collected$2.94M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: KSPHF vs DIVO ($10,000, DRIP)

YearKSPHF PortfolioKSPHF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$11,211$511.04$11,120$420.00+$91.00 → KSPHF
2$12,911$915.07$12,357$458.31+$554.00 → KSPHF
3$15,498$1,683.15$13,721$499.76+$1.8K → KSPHF
4$19,810$3,226.98$15,227$544.58+$4.6K → KSPHF
5$27,784$6,588.10$16,885$593.02+$10.9K → KSPHF
6$44,488$14,758.54$18,713$645.34+$25.8K → KSPHF
7$85,345$37,743.48$20,724$701.81+$64.6K → KSPHF
8$206,968$115,648.35$22,938$762.73+$184.0K → KSPHF
9$669,396$447,940.65$25,372$828.41+$644.0K → KSPHF
10$3,030,231$2,313,976.52$28,047$899.19+$3.00M → KSPHF

KSPHF vs DIVO: Complete Analysis 2026

KSPHF — Stock

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.

Full KSPHF Calculator →

DIVO — ETF

DIVO is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in DIVO shares.

Full DIVO Calculator →
📬

Get this KSPHF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KSPHF vs SCHDKSPHF vs JEPIKSPHF vs OKSPHF vs KOKSPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.